Loading
Cyclacel Pharmaceuticals
Cyclacel is a cell-cycle drug company whose nucleoside analogue sapacitabine failed its phase 3 trial in older patients with acute myeloid leukaemia; it now develops CDK and PLK inhibitors.
Also called: Cyclacel Pharmaceuticals, Inc.Cyclacel
Overview
Cyclacel Pharmaceuticals, founded in 1997 with roots in Dundee and headquartered in Berkeley Heights, New Jersey, ran the phase 3 SEAMLESS trial of oral sapacitabine alternating with decitabine in elderly acute myeloid leukaemia, which did not meet its survival endpoint. It continues with the CDK2/9 inhibitor fadraciclib and a PLK1 inhibitor in early trials, registered on ClinicalTrials.gov under Cyclacel as lead sponsor.
Connected
4Similar pages
- CompanyVion Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.
- CompanyJW Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.
- CompanySunesis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.
- CompanyArog Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia, Small-molecule kinase inhibitors.
- CompanyPregLem
- CompanyDenovo Biopharma
Shares Pivotal (registrational) trial, Clinical trial, Small-molecule kinase inhibitors.
- CompanyAgennix
- CompanyLisata Therapeutics
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
cyclacel.com · 1
wikidata.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Add Wikidata ids and Wikipedia links for 48 companies · diff · file
Sourced, not expert-reviewed